-
June 16, 2024
A Tissue Engineered Treg Approach for the Treatment of Acute Ischemic and Inflammatory Diseases (Poster)
-
May 31, 2024
Adoptive Transfer of Murine Engineered T Regulatory Cells Ameliorates Disease in a Model of Lipopolysaccharide Induced Acute Lung Injury (Poster)
-
May 11, 2024
Stable Expression of FOXP3 and Core Tolerogenic Genes by Engineered Human Tregs (Poster)
-
May 07, 2024
Characterization of Allogeneic Engineered Human Tissue-Tregs for Treatment of Acute Inflammatory Disease (Poster)
-
April 23, 2024
Engineered Regulatory T cells ameliorate lung injury in the LPS model of acute lung injury (Poster)
-
March 23, 2024
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes
-
March 07, 2024
A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells
-
October 24, 2023
A novel engineered Treg platform that addresses Treg stability, IL-2 signaling and targeting, for the treatment of autoimmune diseases (Poster)
-
October 04, 2023
Adoptive Transfer of Murine Engineered T Regulatory Cells Ameliorates Disease in a Model of Lipoplysaccharide Induced Acute Lung Injury
-
June 20, 2023
Human Engineered Tregs maintain stability in inflammatory environment (Poster)
-
May 23, 2023
Development of GNTI-122, a novel engineered regulatory T cell therapeutic, for future application in type 1 diabetes (Poster)
-
May 16, 2023
GNTI-122 is a Dual-Engineered Regulatory T Cell Therapy Product for Type 1 Diabetes with Enhanced Stability, Tissue Specificity, and Tunable IL-2 Signaling (Poster)
-
October 11, 2022
Development and characterization of GNTI-122, an autologous engineered human regulatory T cell therapy for type 1 diabetes (Poster)
-
June 05, 2022
Characterization and efficacy of engineered regulatory T-cell therapy, GNTI-122, for treating Type 1 Diabetes (Poster)
-
May 18, 2022
Generation of Islet-specific Engineered Regulatory T Cells (EngTregs) for Immune Tolerance Induction in Type 1 Diabetes Using a Novel Dual-editing Strategy
-
June 03, 2020
Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function
Toggle navigation